Overview
Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-12-01
2025-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Evaluate the safety and tolerability of RMC-6236 in adults with KRAS p.G12 mutant advanced solid tumors, KRAS p.G12C excluded.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Revolution Medicines, Inc.
Criteria
Inclusion Criteria:- Histologically confirmed advanced solid tumor with KRAS p.G12A, KRAS p.G12D, KRAS
p.G12R, KRAS p.G12S, or KRAS p.G12V mutations identified through deoxyribonucleic acid
(DNA) sequencing.
- Received prior standard therapy appropriate for tumor type and stage
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate organ function
Exclusion Criteria:
- Tumor harboring the KRAS p.G12C mutation
- Primary central nervous system (CNS) tumors
- Known or suspected leptomeningeal or brain metastases or spinal cord compression
- Known or suspected impairment of gastrointestinal function that may prohibit ability
to swallow or absorb an oral medication
- History of any other unstable or clinically significant concurrent medical condition
that would, in the opinion of the investigator, jeopardize the safety of a
participant, impact their expected survival through the end of the study
participation, and/or impact their ability to comply with the protocol
prior/concomitant therapy